BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Vascepa (Icosapent Ethyl) readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Vascepa (Icosapent Ethyl)\, from Clinical
 Trials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06710080-1037@assetmemo.bio
DTSTAMP:20261121T004938Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Vascepa (Icosapent Ethyl): Phase 3 readout est. (NCT06710080)
DESCRIPTION:Vascepa (Icosapent Ethyl)\, phase 3.\nStudy: Targeting Vascular
  INflammation in Patients With Community-Acquired Pneumonia\nEstimated pri
 mary completion: 31 December 2026. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/icosapent-ethyl#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT06710080
URL:https://assetmemo.bio/drug/icosapent-ethyl#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07762755-1037@assetmemo.bio
DTSTAMP:20261121T004938Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Vascepa (Icosapent Ethyl): Phase 4 readout est. (NCT07762755)
DESCRIPTION:Vascepa (Icosapent Ethyl)\, phase 4\, Atherosclerotic Cardiovas
 cular Disease.\nStudy: Icosapent Ethyl for High-Risk Coronary Plaques Asse
 ssed by 18F-NaF PET/CT\nEstimated primary completion: 31 December 2028. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/icosapent-ethyl#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT07762755
URL:https://assetmemo.bio/drug/icosapent-ethyl#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
